SBFMW News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SB

Loading chart

SB

SBFMWSunshine Biopharma Inc. warrant

SBFMW

Pay with—

Available Balance0.00

SB

Mkt Cap

N/A

Volume

N/A

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Why Sunshine Biopharma (SBFM) Stock Dropped After Hours TodaySunshine Biopharma (NASDAQ:SBFM) shares fell 5.17% to $0.30 in after-hours trading following the announcement of a one-for-ten reverse stock split effective June 1, 2026. The reverse split was undertaken to regain compliance with Nasdaq's minimum bid price requirement. The stock has declined 77.99% over the past 12 months and currently has a market capitalization of approximately $5.18 million.Benzinga · May 29, 2026

Sunshine Biopharma Moves Principal Office to New York CityNEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has moved its headquarters to New York City. The Company’s Head Office is now located at 1177 Avenue of the Americas, 5th Floor, New York, NY 10036 (Tel: 332-216-1147). The Company will maintain a satellite office at its previous headquarters in Montreal (Canada) at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada, H9R 0A5 (Tel: 514-426-6161). The Company’s email address ([email protected]) and URL (www.sunshinebiopharma.com) have not changed.GlobeNewswire Inc. · Dec 4, 2023

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%MONTREAL, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 second quarter. The Company reported gross revenues of $5,560,865 for the quarter ended June 30, 2023, an increase of 3,600% over the same period in 2022. The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a generic pharmaceuticals company that Sunshine Biopharma acquired in October 2022. In addition, the Company’s second quarter revenues of $5,560,865 represent a 13.6% increase over first quarter results.GlobeNewswire Inc. · Aug 11, 2023

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-MarketMONTREAL, May 16, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.GlobeNewswire Inc. · May 16, 2023

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-MarketMONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.GlobeNewswire Inc. · May 12, 2023

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate UpdateMONTREAL, April 05, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced reporting of operating results for the fiscal year ended December 31, 2022 and recent highlights.GlobeNewswire Inc. · Apr 5, 2023

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer CompoundMONTREAL, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of a research agreement with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada. The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through the IND-enabling studies. At any time the research results become conclusive and Sunshine Biopharma wishes to proceed to conducting a Phase I clinical trial, the Jewish General Hospital is prepared to negotiating a new agreement to define the responsibilities and obligations of the parties for such Phase I clinical trial to be performed.GlobeNewswire Inc. · Feb 10, 2023

Sunshine Biopharma Announces Share Repurchase ProgramMONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company’s common stock.GlobeNewswire Inc. · Jan 19, 2023

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of ArizonaMONTREAL, July 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has agreed to provide additional resources to the University of Arizona R. Ken Coit College of Pharmacy for the purposes of accelerating the development of novel PLpro inhibitors currently underway. The development of the Company’s lead PLpro inhibitor, SBFM-PL4, is continuing in parallel.GlobeNewswire Inc. · Jul 28, 2022

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-MarketMONTREAL, April 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously announced private placement pursuant to a securities purchase agreement entered into on April 25, 2022 with certain institutional and accredited investors for aggregate gross proceeds of approximately $19.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.GlobeNewswire Inc. · Apr 28, 2022

to start trading

SB

SBFMWSunshine Biopharma Inc. warrant

SBFMW

Pay with—

Available Balance0.00

Your PositionYou don't own any SBFMW yet.

Related Tickers

Earnings